Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Carlsmed (CARL) EBIT (2024 - 2025)

Carlsmed's EBIT history spans 2 years, with the latest figure at -$9.3 million for Q4 2025.

  • For Q4 2025, EBIT fell 98.38% year-over-year to -$9.3 million; the TTM value through Dec 2025 reached -$29.6 million, changed N/A, while the annual FY2025 figure was -$30.6 million, 26.75% down from the prior year.
  • EBIT reached -$9.3 million in Q4 2025 per CARL's latest filing, down from -$9.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$4.7 million in Q4 2024 to a low of -$9.3 million in Q4 2025.